NASDAQ:NERV Minerva Neurosciences Q1 2025 Earnings Report $1.63 0.00 (-0.07%) As of 05/13/2025 12:18 PM Eastern Earnings HistoryForecast Minerva Neurosciences EPS ResultsActual EPS-$0.50Consensus EPS -$1.07Beat/MissBeat by +$0.57One Year Ago EPSN/AMinerva Neurosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMinerva Neurosciences Announcement DetailsQuarterQ1 2025Date5/13/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Minerva Neurosciences Earnings HeadlinesMinerva Neurosciences Reports First Quarter 2025 Financial Results and Business UpdatesMay 13 at 7:30 AM | globenewswire.comMinerva Neurosciences (NERV) Expected to Announce Quarterly Earnings on WednesdayMay 6, 2025 | americanbankingnews.comWhy America’s building cathedrals againWhile the media fixates on tariffs and market noise, something historic is unfolding behind the scenes. With backing from the White House and Silicon Valley billionaires, a vast network of AI-powered facilities is taking shape across the country. They’re being called “Cathedrals of Light” — and they hold the keys to nuclear fusion, advanced medicine, and defense breakthroughs. I’ve spent 25 years identifying seismic shifts like this — and I believe this could be the biggest one yet for early investors.May 14, 2025 | Porter & Company (Ad)Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.comMay 6, 2025 | americanbankingnews.comMinerva Neurosciences Inc.April 23, 2025 | barrons.comMinerva Neurosciences regains Nasdaq complianceMarch 21, 2025 | investing.comSee More Minerva Neurosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Minerva Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Minerva Neurosciences and other key companies, straight to your email. Email Address About Minerva NeurosciencesMinerva Neurosciences (NASDAQ:NERV), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.View Minerva Neurosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery?Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Upcoming Earnings Cisco Systems (5/14/2025)Toyota Motor (5/14/2025)Applied Materials (5/15/2025)Copart (5/15/2025)NetEase (5/15/2025)Alibaba Group (5/15/2025)Deere & Company (5/15/2025)Mizuho Financial Group (5/15/2025)National Grid (5/15/2025)Walmart (5/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
